Wong Newton A C S, Gonzalez David, Salto-Tellez Manuel, Butler Rachel, Diaz-Cano Salvador J, Ilyas Mohammad, Newman William, Shaw Emily, Taniere Philippe, Walsh Shaun V
J Clin Pathol. 2014 Sep;67(9):751-7. doi: 10.1136/jclinpath-2014-202467.
Analysis of colorectal carcinoma (CRC) tissue for KRAS codon 12 or 13 mutations to guide use of anti-epidermal growth factor receptor (EGFR) therapy is now considered mandatory in the UK. The scope of this practice has been recently extended because of data indicating that NRAS mutations and additional KRAS mutations also predict for poor response to anti-EGFR therapy. The following document provides guidance on RAS (i.e., KRAS and NRAS) testing of CRC tissue in the setting of personalised medicine within the UK and particularly within the NHS. This guidance covers issues related to case selection, preanalytical aspects, analysis and interpretation of such RAS testing.
在英国，对结直肠癌（CRC）组织进行KRAS密码子12或13突变分析以指导抗表皮生长因子受体（EGFR）治疗的使用现已被视为必要操作。由于有数据表明NRAS突变和额外的KRAS突变也预示着对抗EGFR治疗反应不佳，这种做法的范围最近有所扩大。以下文件就英国尤其是国民保健制度（NHS）内个性化医疗背景下CRC组织的RAS（即KRAS和NRAS）检测提供指导。本指导涵盖与病例选择、分析前方面、此类RAS检测的分析和解读相关的问题。
